This product is a quinolone antibacterial drug, which has antibacterial effects on Gram-negative bacteria, such as Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Serratia, Salmonella typhi, Shigella, Pseudomonas aeruginosa, etc. This product acts on bacterial DNA gyrase, interfering with the synthesis of bacterial DNA, thereby causing bacterial death.

Rifampicin is a semi-synthetic broad-spectrum antibacterial drug of the rifamycin class, which has antibacterial activity against a variety of pathogenic microorganisms. The drug has a significant bactericidal effect on Mycobacterium tuberculosis and some non-tuberculous mycobacteria (including Mycobacterium leprae, etc.) both inside and outside the host cells. Rifampicin has a good antibacterial effect on aerobic Gram-positive bacteria, including enzyme-producing strains of Staphylococcus and methicillin-resistant strains, Streptococcus pneumoniae, other Streptococcus, Enterococcus, Listeria, Bacillus anthracis, Clostridium perfringens, Corynebacterium diphtheriae, anaerobic cocci, etc. It also has a high degree of antibacterial activity against aerobic Gram-negative bacteria such as Neisseria meningitidis, Haemophilus influenzae, and Neisseria gonorrhoeae. Rifampicin also has a good effect on Legionella, and has an inhibitory effect on pathogens such as Chlamydia trachomatis, lymphogranuloma venereum, and psittacosis. Bacteria have cross-resistance to rifamycin antibiotics. Rifampicin binds firmly to the β-subunit of DNA-dependent RNA polymerase, inhibiting the synthesis of bacterial RNA and preventing the enzyme from connecting to DNA, thereby blocking the RNA transcription process and stopping the synthesis of DNA and protein.

Rifampicin is a semi-synthetic broad-spectrum antibacterial drug of the rifamycin class, which has antibacterial activity against a variety of pathogenic microorganisms. The drug has a significant bactericidal effect on Mycobacterium tuberculosis and some non-tuberculous mycobacteria (including Mycobacterium leprae, etc.) both inside and outside the host cells. Rifampicin has a good antibacterial effect on aerobic Gram-positive bacteria, including enzyme-producing strains of Staphylococcus and methicillin-resistant strains, Streptococcus pneumoniae, other Streptococcus, Enterococcus, Listeria, Bacillus anthracis, Clostridium perfringens, Corynebacterium diphtheriae, anaerobic cocci, etc. It also has a high degree of antibacterial activity against aerobic Gram-negative bacteria such as Neisseria meningitidis, Haemophilus influenzae, and Neisseria gonorrhoeae. Rifampicin also has a good effect on Legionella, and has an inhibitory effect on pathogens such as Chlamydia trachomatis, lymphogranuloma venereum, and psittacosis. Bacteria have cross-resistance to rifamycin antibiotics. Rifampicin binds firmly to the β-subunit of DNA-dependent RNA polymerase, inhibiting the synthesis of bacterial RNA and preventing the enzyme from connecting to DNA, thereby blocking the RNA transcription process and stopping the synthesis of DNA and protein.

This product is a broad-spectrum antibacterial agent, with bactericidal effect at high concentrations. It has antibacterial effects on Streptococcus pneumoniae, hemolytic Streptococcus, Streptococcus viridans, some Staphylococci, Clostridium perfringens, Bacillus anthracis, Yersinia pestis, Corynebacterium diphtheriae, Clostridium tetani, Brucella, Haemophilus influenzae, Campylobacter, Vibrio cholerae, etc. It also has inhibitory effects on Rickettsia, Mycoplasma, Chlamydia, Spirochete, and some protozoa. It specifically binds to the A position of the 30S subunit of the bacterial ribosome, preventing the connection of aminoacyl-tRNA at this position, thereby inhibiting the growth of peptide linkages and affecting the synthesis of bacterial proteins.

This product is a third-generation angiotensin converting enzyme inhibitor, which can inhibit the activity of angiotensin converting enzyme, reduce the concentration of angiotensin II and aldosterone, increase plasma renin activity, lead to peripheral vasodilation and decreased vascular resistance, and thus produce a hypotensive effect. The hypotensive effect occurs within about 2 hours after oral administration, and the maximum hypotensive effect occurs about 4 to 6 hours after oral administration, which is consistent with the peak time of blood drug concentration (tmax). The hypotensive effect lasts for 24 hours, and there will be no blood pressure rebound after stopping the drug, and there is no significant change in heart rate after taking the drug.